Sun Pharmaceutical Industries launches Favipiravir to treat COVID!
Galatta | Aug 05, 2020, 07:20 pm
Ever since the COVID-19 Novel Corona Virus Pandemic's outbreak, teams of researchers and scientists have been working round the clock to identify a cure or vaccine for this deadly virus! Many different vaccines are close to becoming reality and a number of them are in the final stage of testing! Meanwhile, based on the severity of the Virus attack in patients, doctors are using different medicines to treat the COVID patients! Initially, the anti-malarial drug Hydroxychloroquine was considered to be a good medicine to treat COVID infected patients but soon many healthcare professionals voiced out against it, stating it had too many side effects! Now, the anti-viral drug Favipiravir is being launched by Sun Pharmaceutical Industries to treat mild to moderate infections of COVID!
Favipiravir is the only oral anti-viral drug allowed approved for the potentially treating COVID patients in India and now a 200mg dosage tablet of this drug is being launched by Sun Pharma for usage in India. The company is launching the tablet under the name FluGuard and that too at a very affordable, economic price of just Rs. 35 per tablet! Kirti Ganorkar - the CEO of Indian business at Sun Pharma, said, "With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals.” She also mentioned that they are launching FluGuard at an economical rate to make the drug accessible to more and more patients and meanwhile, reducing their financial burden too! Ms. Kirti mentioned, "This is in line with our continuous efforts to support India's pandemic response!"
Sun Pharmaceutical Industries Ltd., has said that it will work in hand with the government and the medical fraternity to ensure availability of FluGuard to all needy patients across the country. As per reports, the stocks of this tablet will be available in the market, from as early as this week itself! Similar to Favipiravir, Glenmark's FabiFlu is also available at Rs. 75 per tablet after the company decided to reduce the tablet's price from the Rs. 103, it was originally being sold at when it was introduced. Sun Pharma is reportedly the fourth- largest speciality generic pharmaceutical company in the world and the top company in its field, in India! Stay tuned for updates...